Horm Metab Res
DOI: 10.1055/a-2291-0340
Original Article: Endocrine Care
Xian Cheng
1
NHC Key Laboratory of Nuclear Medicine, Jiangsu Institute of Nuclear
Medicine, Wuxi, China
,
Yijun Fan
1
NHC Key Laboratory of Nuclear Medicine, Jiangsu Institute of Nuclear
Medicine, Wuxi, China
,
Wanzhong Ye
1
NHC Key Laboratory of Nuclear Medicine, Jiangsu Institute of Nuclear
Medicine, Wuxi, China
,
Shichen Xu
1
NHC Key Laboratory of Nuclear Medicine, Jiangsu Institute of Nuclear
Medicine, Wuxi, China
,
Jing Wu
1
NHC Key Laboratory of Nuclear Medicine, Jiangsu Institute of Nuclear
Medicine, Wuxi, China
,
Wenjing Gao
1
NHC Key Laboratory of Nuclear Medicine, Jiangsu Institute of Nuclear
Medicine, Wuxi, China
,
Jiandong Bao
1
NHC Key Laboratory of Nuclear Medicine, Jiangsu Institute of Nuclear
Medicine, Wuxi, China
,
Huixin Yu
1
NHC Key Laboratory of Nuclear Medicine, Jiangsu Institute of Nuclear
Medicine, Wuxi, China
,
Li Zhang
1
NHC Key Laboratory of Nuclear Medicine, Jiangsu Institute of Nuclear
Medicine, Wuxi, China
› Author Affiliations
Funding Information
Science and Research Foundation of Wuxi Science & Technology Bureau — Y20212051
Y20212052
Wuxi Health Commission — Q202103
Science and Research Foundation of the Health Bureau of Jiangsu Province —
M2021060
National Natural Science Foundation of China —
http://dx.doi.org/10.13039/501100001809; 81972503 82103656
› Further Information
Also available at
![SFX Search]()
Buy Article Permissions and Reprints
Abstract
Our previous study showed that elevated preoperative thyroglobulin (pre-Tg) level
predicted the risk of developing radioiodine refractory in PTC patients. In the
present study, we aimed to evaluate the prognostic value of pre-Tg in papillary
thyroid microcarcinoma (PTMC). After a specific inclusion and exclusion criteria
were applied, a total of 788 PTMCs were enrolled from Jiangyuan Hospital
affiliated to Jiangsu Institute of Nuclear Medicine between Jan 2015 and Dec
2019. Among them, 107 PTMCs were treated with radioiodine therapy (RAIT) and the
response to therapy was grouped as excellent response (ER), and non-excellent
response (NER: indeterminate response, IDR and biochemical incomplete response,
BIR). Multivariable logistic regression was used to identify predictors for the
response of RAIT in PTMCs. Higher pre-Tg levels were detected in PTMCs with RAIT
as compared with PTMCs without RAIT (p=0.0018). Higher levels of pre-Tg were
also found in patients with repeated RAIT as compared with patients with single
RAIT (p<0.0001). Furthermore, pre-Tg level was higher in PTMC with IDR (n=16)
and much higher in BIR (n=9) as compared with patients with ER (n=82, p=0.0003)
after RAIT. Multivariate analysis showed that pre-Tg level over 16.79 ng/ml [OR:
6.55 (2.10–20.39), p=0.001] was the only independent predictor for NER in PTMC
with RAIT. We found that high level of pre-Tg predicted a poor RAIT outcome in
PTMC. Our finding explores a prospective way in identifying high-risk PTMCs with
poor response to RAIT.
Keywords
PTMC -
preoperative thyroglobulin -
radioiodine therapy -
prognosis
Publication History
Received: 22 September 2023
Accepted after revision: 19 March 2024
Accepted Manuscript online:
19 March 2024
Article published online:
15 April 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart,
Germany
References
1
Lee JS,
Lee JS,
Yun HJ.
et al.
Aggressive subtypes of papillary thyroid carcinoma smaller than 1 cm. J Clin Endocrinol Metab 2023; 108: 1370-1375
2
Haugen BR,
Alexander EK,
Bible KC.
et al.
2015 American thyroid association management guidelines for adult patients with
thyroid nodules and differentiated thyroid cancer: the american thyroid
association guidelines task force on thyroid nodules and differentiated thyroid
cancer. Thyroid 2016; 26: 1-133
3
Sugitani I,
Toda K,
Yamada K.
et al.
Three distinctly different kinds of papillary thyroid microcarcinoma should be
recognized: our treatment strategies and outcomes. World J Surg 2010; 34: 1222-1231
4
Ito Y,
Miyauchi A,
Kihara M.
et al.
Patient age is significantly related to the progression of papillary
microcarcinoma of the thyroid under observation. Thyroid 2014; 24: 27-34
5
Baloch ZW,
Asa SL,
Barletta JA.
et al.
Overview of the 2022 who classification of thyroid neoplasms. Endocr Pathol 2022; 33: 27-63
6
Han B,
Hao S,
Wu J.
et al.
Predictive features of central lymph node metastasis in papillary thyroid
microcarcinoma: roles of active surveillance in over-treatment. Front Med (Lausanne) 2022; 9: 906648
7
Citterio CE,
Targovnik HM,
Arvan P.
The role of thyroglobulin in thyroid hormonogenesis. Nat Rev Endocrinol 2019; 15: 323-338
8
Huang Z,
Song M,
Wang S.
et al.
Preoperative serum thyroglobulin is a risk factor of skip metastasis in
papillary thyroid carcinoma. Ann Transl Med 2020; 8: 389
9
Kim H,
Kim YN,
Kim HI.
et al.
Preoperative serum thyroglobulin predicts initial distant metastasis in patients
with differentiated thyroid cancer. Sci Rep 2017; 7: 16955
10
Kim H,
Park SY,
Choe JH.
et al.
Preoperative serum thyroglobulin and its correlation with the burden and extent
of differentiated thyroid cancer. Cancers (Basel) 2020; 12: 625
11
Cheng X,
Xu SC,
Zhu Y.
et al.
Markedly elevated serum preoperative thyroglobulin predicts
radioiodine-refractory thyroid cancer. Eur J Clin Invest 2021; 52: e13721
12
Brito JP,
Ito Y,
Miyauchi A.
et al.
A clinical framework to facilitate risk stratification when considering an
active surveillance alternative to immediate biopsy and surgery in papillary
microcarcinoma. Thyroid 2016; 26: 144-149
13
Perrier ND,
Brierley JD,
Tuttle RM.
Differentiated and anaplastic thyroid carcinoma: Major changes in the american
joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin 2018; 68: 55-63
14
Petric R,
Besic H,
Besic N.
Preoperative serum thyroglobulin concentration as a predictive factor of
malignancy in small follicular and hurthle cell neoplasms of the thyroid
gland. World J Surg Oncol 2014; 12: 282
15
Oltmann SC,
Leverson G,
Lin SH.
et al.
Markedly elevated thyroglobulin levels in the preoperative thyroidectomy patient
correlates with metastatic burden. J Surg Res 2014; 187: 1-5
16
Park JH,
Choi M,
Kim JH.
et al.
Metabolic syndrome and the risk of thyroid cancer: a nationwide population-based
cohort study. Thyroid 2020; 30: 1496-1504
17
Walter LB,
Scheffel RS,
Zanella AB.
et al.
Active surveillance of differentiated thyroid cancer metastatic cervical lymph
nodes: a retrospective single-center cohort study. Thyroid 2023; 33: 312-320
18
Chen Y,
Sa R,
Qiu X.
et al.
Second radioiodine treatment hardly benefits tt-dtc patients with
radioiodine-negative metastases on initial post-therapeutic whole-body
scans. Q J Nucl Med Mol Imaging 2023; 67: 294-303
19
Yan L,
Liu Y,
Li W.
et al.
Long-term outcomes of ultrasound-guided thermal ablation for the treatment of
solitary low-risk papillary thyroid microcarcinoma: a multicenter retrospective
study. Ann Surg 2023; 277: 846-853
20
Hauch A,
Al-Qurayshi Z,
Randolph G.
et al.
Total thyroidectomy is associated with increased risk of complications for low-
and high-volume surgeons. Ann Surg Oncol 2014; 21: 3844-3852
21
Gao M,
Ge M,
Ji Q.
et al.
2016 chinese expert consensus and guidelines for the diagnosis and treatment of
papillary thyroid microcarcinoma. Cancer Biol Med 2017; 14: 203-211
22
Lee JS,
Lee JS,
Yun HJ.
et al.
Aggressive subtypes of papillary thyroid carcinoma smaller than 1 cm. J Clin Endocrinol Metab 2023; 108: 1370-1375
23
Piana S,
Ragazzi M,
Tallini G.
et al.
Papillary thyroid microcarcinoma with fatal outcome: Evidence of tumor
progression in lymph node metastases: Report of 3 cases, with morphological and
molecular analysis. Hum Pathol 2013; 44: 556-565
24
Wang Z,
Guan H.
Hear the patient's voice regarding implementation of thyroid cancer active
surveillance in china. Thyroid 2023; 33: 782-784
25
Chang Q,
Zhang J,
Wang Y.
et al.
Nomogram model based on preoperative serum thyroglobulin and clinical
characteristics of papillary thyroid carcinoma to predict cervical lymph node
metastasis. Front Endocrinol (Lausanne) 2022; 13: 937049
留言 (0)